Edoxaban,Markets and News,API,Edoxaban,480449-70-5,ANQING CHICO PHARMACEUTICAL

Abstract

Edoxaban, marketed under the brand name Lixiana, is a direct oral anticoagulant (DOAC) utilized for preventing and treating various thromboembolic disorders. Developed by Daiichi Sankyo, it received regulatory approvals starting in 2011. This paper provides an in-depth analysis of edoxaban, including its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations. Additionally, it offers speculative sales figures from 2020 to 2024 based on available data and market trends.

Keywords

Edoxaban, Lixiana, direct oral anticoagulant, chemical properties, market analysis, global sales, generics.

Introduction

Edoxaban is a direct factor Xa inhibitor that impedes blood clot formation by selectively inhibiting factor Xa, an essential enzyme in the coagulation cascade. Its development aimed to provide an alternative to traditional anticoagulants like warfarin, offering advantages such as predictable pharmacokinetics, fixed dosing, and no requirement for routine coagulation monitoring.

Chemical Properties

Edoxaban has the chemical formula C24H30ClN7O4S and a molar mass of approximately 548.06 g·mol−1. Its IUPAC name is N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide. The molecular structure of edoxaban facilitates its role as a selective inhibitor of factor Xa, contributing to its efficacy as an anticoagulant.

Development and Approval Timeline

Edoxaban was developed by Daiichi Sankyo and was first approved in Japan in 2011 under the brand name Lixiana. Subsequently, it received approvals in various countries, including the European Union and the United States, for multiple indications such as stroke prevention in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism.

Time on the Market

Since its initial approval in 2011, edoxaban has been available for over a decade. Its sustained presence in the market reflects its acceptance among healthcare providers and patients, attributed to its efficacy and convenience compared to traditional anticoagulants.

Global Sales and Market Competition

Specific global sales figures for edoxaban are not readily available. However, the global direct oral anticoagulants (DOACs) market was valued at approximately $43.9 billion in 2023 and is projected to reach $102.36 billion by 2034, growing at a compound annual growth rate (CAGR) of 8% from 2024 to 2034. citeturn0search6 Edoxaban competes with other DOACs such as rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa). Factors influencing market share include efficacy, safety profiles, cost, and patient preferences.

Generics and Related Developments

The patent for edoxaban expired in 2021, leading to the introduction of generic formulations in various markets. The availability of generics has increased accessibility and reduced costs, aligning with global efforts to make anticoagulant therapies more affordable. However, the influx of generic versions has intensified market competition, potentially impacting the market share of original brand-name products.

Speculated Sales Figures (2020–2024)

While exact sales data for edoxaban from 2020 to 2024 are not publicly available, we can speculate based on market trends and available data:

• 2020: Approximately $1.5 billion

• 2021: Approximately $1.8 billion

• 2022: Approximately $2.0 billion

• 2023: Approximately $2.2 billion

• 2024: Approximately $2.4 billion

These figures reflect a compound annual growth rate (CAGR) of approximately 10% from 2020 to 2024, consistent with the growth observed in the DOAC market.

Conclusion

Edoxaban has significantly impacted the anticoagulant market since its introduction, offering advantages over traditional therapies. Its development and sustained market presence underscore its importance in managing thromboembolic disorders. The advent of generic versions has expanded its reach, enhancing accessibility while introducing new competitive dynamics. As the market evolves, edoxaban's role in clinical practice will continue to be influenced by ongoing research, regulatory developments, and shifts in prescribing patterns.

Active Pharmaceutical Ingredient
480449-70-5
Edoxaban, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.